Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Consistent with the base-case analysis, sensitivity analyses demonstrated that using GLP-1RAs versus insulin was either cost-saving or cost-effective, except for the analyses where the treatment effectiveness was estimated based on the AT scenario in the second and third sensitivity analyses, showing that a GLP-1RA versus insulin therapy was not cost-effective for averting one case of all-cause death from the payer perspective
doi:10.1002/14651858.CD009183.pub2
Open the full third-party lab report for this batch
Log in here
B.BartelD
Nutrients 16 (16), 2753
US$ 21.52
US$ 29.52
US$ 21.97
US$ 23.02
